FAQ: NanoViricides' NV-387 Measles Treatment Breakthrough
Summary
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus in both cell culture studies and humanized animal models, extending survival in infected mice by 130% while protecting lung tissue from damage. This represents significant potential as a first-in-class therapeutic since no approved drug currently exists for Measles treatment.
What is NV-387 and what did the study demonstrate?
NV-387 is NanoViricides’ clinical lead drug candidate that demonstrated potent antiviral effects against the Measles virus in both cell culture studies and a humanized animal model. The treatment extended survival in infected mice by 130% (from 7.4 to 17 days) while significantly protecting lung tissue from viral and immune-related damage.
Why is this development significant for Measles treatment?
This development is significant because no approved drug currently exists for Measles treatment, making NV-387 a potential first-in-class therapeutic candidate. The drug’s dual action of direct viral suppression and mitigation of systemic and lung inflammation showed reduced lung plaques, slower disease progression and improved overall health outcomes.
How does NV-387 work against Measles infection?
NV-387 works through dual action - direct viral suppression and mitigation of systemic and lung inflammation. The drug demonstrated reduced lung plaques, slower disease progression and improved overall health outcomes in treated animals by protecting lung tissue from both viral and immune-related damage.
What is NanoViricides and what is their business model?
NanoViricides, Inc. is a publicly traded clinical stage company creating special purpose nanomaterials for antiviral therapy. Their business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
What other viral diseases is NV-387 being developed for?
NV-387 is a broad-spectrum antiviral drug that NanoViricides plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
What other drug candidates does NanoViricides have in development?
NanoViricides’ other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is also developing drugs against numerous viral diseases including oral and genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
What is the current status of NV-387’s development?
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. However, the company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.
Where can I find more information about this announcement?
To view the full press release, visit https://ibn.fm/MhcmX. More information about NanoViricides can be found at their website: https://www.nanoviricides.com/.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 262308